OncoMasTR is a multi-parameter prognostic test for ER-positive, HER2-negative early stage breast cancer patients with up to 3 involved lymph nodes.

The OncoMasTR RT-qPCR test measures the expression of 3 prognostic genes (+ 3 reference genes) and estimates the probability of distant recurrence for breast cancer patients, thereby aiding clinicians in determining the best treatment options for their patients and avoiding the costs and severe side-effects from unwarranted chemotherapy, ultimately improving the quality of life of the patient. 


Advantages of OncoMasTR :

- Validated Clinical Performance

- Quality and Cost-effectiveness

- Ease of Use

- Scientific Foundation



Validated Clinical Performance

Clinically validation study using the TransATAC cohort (n=646) [1] demonstrated:

  1. Classification of >55% of LN0 patients in the low risk group, which has <5% risk of distant recurrence (DR)
  2. Significantly prognostic for patients with LN0 and LN-1 to 3 diseases
  3. Significantly prognostic for early recurrence (years 0-5) and late recurrence (years 5-10)
  4. Adds significant prognostic value to clinical information such as Ki67, Nottingham Pognostic Index (NPI) and Clincal Treatment Score (CTS)

Benchmarked against market-leader Oncotype DX Recurrence Score (RS) in an independent study[2] using 403 samples from Irish patients enrolled in the TAILORx trial - OncoMasTR accurately reclassified RS intermediate risk patients:

  1. Using the TAILORx trial-defined RS risk classification, OncoMasTR Test reclassified 69% of RS intermediate risk patients into low risk, with 7 out of 8 patients who experienced DR reclassified as high risk
  2. Using the routine clinical RS risk classification, OncoMasTR Test reclassified 57% of RS intermediate risk patients into low risk, with all 5 patients who experienced DR reclassified as high risk


Ease of Use

The OncoMasTR test is performed locally, so there is no need to send away clinical specimens. The test uses FFPE specimens and enables results in less than one day.


Scientific Foundation

The OncoMasTR Risk Score considers tumour size and lymph node status in addition to its discrete, high information-content 3 MTRs that were shown to regulate biomarkers in other breast cancer prognostic signatures.[3]



[1] Buus R, Sestak I, Barron S et al. Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study. Clin Cancer Res February 1 2020 (26) (3) 623-631; DOI: 10.1158/1078-0432.CCR-19-0712

[2] Kelly CM, Crown J, Russell N et al. Comparison of the prognostic performance between OncoMasTR and Oncotype DX multigene signatures in HR-positive, HER2-negative, lymph node-negative breast cancer. DOI: 10.1200/JCO.2018.36.15_suppl.12074 Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 12074-12074.

[3] Lanigan F. et al. Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. FEBS, 2015. 282(18): 3455-73.